Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Fetal Compartment (Placenta and Amniotic Fluid)
Authors:
- 1 November 2011
- journal article
- review article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 16 (8) , 1139-1147
Abstract
HIV resides within anatomical ‘sanctuary sites’ where local drug exposure and viral dynamics may differ significantly from the systemic compartment. Widespread implementation of antiretroviral therapy has seen a significant decline in the incidence of mother-to-child transmission (MTCT) of HIV. In addition to suppression of maternal plasma/genital viral loads, antiretroviral agents that cross the placenta and achieve adequate concentrations in the fetal compartment may exert a greater prophylactic effect. Penetration of antiretrovirals in the fetal compartment is expressed by accumulation ratios derived from the measurement of drug concentrations in paired maternal plasma and umbilical cord samples. The nucleoside analogues and nevirapine accumulate extensively in cord blood and in the surrounding amniotic fluid, whereas the protease inhibitors (PIs) exhibit low-to-moderate placental accumulation. Early data suggest that high placental/neonatal concentrations are achieved with raltegravir, but to a lesser extent with etravirine and maraviroc (rank order of accumulation: raltegravir/nucleoside reverse transcriptase inhibitor [tenofovir > zidovudine/lamivudine/emtricitabine/stavudine/abacavir] > non-nucleoside reverse transcriptase inhibitor [nevirapine > etravirine] > PI > maraviroc/enfuvirtide). More comprehensive in vivo pharmacokinetic data are required to justify the potential use of these agents as safe and effective options during pregnancy.Keywords
This publication has 95 references indexed in Scilit:
- Maternal-Fetal Pharmacokinetics and Dynamics of a Single Intrapartum Dose of Maraviroc in Rhesus MacaquesAntimicrobial Agents and Chemotherapy, 2010
- Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safetyAIDS, 2010
- Genital Tract, Cord Blood, and Amniotic Fluid Exposures of Seven Antiretroviral Drugs during and after Pregnancy in Human Immunodeficiency Virus Type 1-Infected WomenAntimicrobial Agents and Chemotherapy, 2009
- Population Pharmacokinetics of Emtricitabine in Human Immunodeficiency Virus Type 1-Infected Pregnant Women and Their NeonatesAntimicrobial Agents and Chemotherapy, 2009
- Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokineticsHIV Medicine, 2008
- Inhibition of placental P‐glycoprotein: impact on indinavir transfer to the foetusBritish Journal of Clinical Pharmacology, 2007
- Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasmaBritish Journal of Clinical Pharmacology, 2006
- Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virusAmerican Journal of Obstetrics and Gynecology, 2004
- Models for Placental Transfer Studies of DrugsClinical Pharmacokinetics, 1995
- The Significance of Plasma Protein Binding on the Fetal/Maternal Distribution of Drugs at Steady-StateClinical Pharmacokinetics, 1988